- Home
- WPAC vs CCCC Comparison
WPAC vs CCCC Comparison
Compare WPAC & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WPAC | CCCC |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 185.1M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WPAC | CCCC |
|---|---|---|
| Price | $9.96 | $3.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 12.0K | ★ 2.8M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $9.82 | $1.21 |
| 52 Week High | $10.98 | $3.95 |
Technical Indicators
Market Signals| Indicator | WPAC | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 62.62 |
| Support Level | $9.87 | $2.37 |
| Resistance Level | $10.21 | $3.89 |
| Average True Range (ATR) | 0.20 | 0.29 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 0.88 | 69.26 |
Price Performance
Historical ComparisonAbout WPAC White Pearl Acquisition Corp. Class A Ordinary Shares
White Pearl Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.